Bilastine - FAES Farma

Drug Profile

Bilastine - FAES Farma

Alternative Names: Aligrin; Bellozal; Bilador; Bilahist; Bilanoa; Bilaska; Bilaxten; Bilaz; Bilidren; BLEXTEN; Borenar; Clatra; Drynol; F-96221-BM; Fortecal; Gosall; Ibis; Ilaxten; Inorial; Labixten; Lamiastine; Lendin; Lergonix; Nasitop; Nixar; Obalix; Olisir; Omarit; Opexa; Revitelle; Robilas; TAC-202; Vitador; Xados; Zilas

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FAES Farma
  • Developer Aralez Pharmaceuticals Inc.; FAES Farma; Menarini; Taiho Pharmaceutical; Yuhan
  • Class Antiallergics; Benzimidazoles; Eye disorder therapies; Piperidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Perennial allergic rhinitis; Pruritus; Seasonal allergic rhinitis; Urticaria
  • Phase III Allergic rhinoconjunctivitis
  • Discontinued Angioedema

Most Recent Events

  • 26 Feb 2018 Phase-III clinical trials in Allergic conjunctivitis in USA (Ophthalmic) (NCT03479307)
  • 11 Oct 2017 Faes Farma completes a phase II trial in Allergic conjunctivitis in USA (Ophthalmic) (NCT03231969)
  • 01 Jul 2017 Phase-II clinical trials in Allergic conjunctivitis in USA (Ophthalmic) (NCT03231969)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top